Related Experiment Video
Updated: Jun 2, 2026
08:43
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
[Bladder preservation using chemoradiation therapy for locally invasive bladder cancer]
Toyofumi Abe1, Toshiaki Yoshioka, Mototaka Sato
1Department of Urology, Sumitomo Hospital.
Summary
Chemoradiation therapy offers successful bladder preservation for invasive bladder cancer, achieving survival rates comparable to radical cystectomy. Bcl-x expression may predict treatment outcomes in these patients.
Area of Science:
- Urology
- Oncology
- Radiation Oncology
Context:
- Invasive bladder cancer presents significant treatment challenges.
- Radical cystectomy is a standard but morbid treatment option.
- Organ preservation strategies are sought to improve quality of life.
Purpose:
- To evaluate long-term outcomes of bladder-sparing chemoradiation therapy for invasive bladder cancer.
- To identify molecular markers predicting treatment response and survival.
- To assess the feasibility of selective organ preservation in this patient cohort.
Summary:
- Thirty-two patients with locally invasive bladder cancer received transurethral resection of bladder tumor (TURBT) followed by chemoradiation (46 Gy radiotherapy and concurrent cisplatin).
- Bladder preservation was achieved in 84.4% of patients, with a 3-year actuarial local control rate of 56.3%.
- Five-year cancer-specific survival rates varied by stage (75.0% for T2, 67.2% for T3, 33.3% for T4).
Impact:
- Chemoradiation therapy provides comparable survival to radical cystectomy while enabling bladder preservation.
- Bcl-x protein expression in pretreatment tumor specimens is a significant negative prognostic marker.
- This study highlights Bcl-x as a potential biomarker for guiding chemoradiation therapy decisions in invasive bladder cancer.
